Your session is about to expire
← Back to Search
ChAd155-RG for Rabies
Study Summary
This trial is testing a new vaccine for rabies virus in adults to see if it is safe and effective. There are 4 groups of people receiving different dosages of either the new vaccine or a placebo, and the trial will take approximately 48 months to complete.
- Rabies
- Rabies Vaccination
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You have a history of certain medical conditions like autoimmune disease, heart, lung, liver, rheumatologic or kidney problems that could significantly affect your health.You are already involved or planning to participate in another clinical study that involves the use of new drugs, taking blood, or undergoing invasive medical procedures that require anesthesia or tissue removal during this trial.You have had a serious allergic reaction to a vaccine or vaccine products in the past.You have a history of long-term hives.You have a history of nervous system disorders such as paralysis, vertigo, or vision problems.You have been vaccinated for rabies before or have had exposure, infection, or disease related to rabies.You are more likely to come into contact with rabies than the average person in the US.You have previously received a vaccine that uses Adenovirus as a carrier.You have a serious mental health condition that, according to the doctor, would make it difficult for you to take part in the study.You have taken part in a study for a new treatment within the last 3 months or plan to do so during this trial.You currently use alcohol or have a history of using recreational or narcotic drugs that could make it hard for you to follow the study requirements.You are currently using chloroquine or hydroxychloroquine.You have a severe allergy or life-threatening reaction to latex.
- Group 1: Arm B
- Group 2: Arm D
- Group 3: Arm A
- Group 4: Arm C
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can I partake in this clinical trial?
"This rabies-related study is seeking up to 50 participants aged between 18 and 49. Eligible applicants must have been diagnosed with the virus in order to join this trial."
Is this investigation open to those aged fifty and beyond?
"This clinical trial is only open to patients aged 18-49. However, there are 13 trials for minors and 11 for the elderly who require medical attention."
How many patients are participating in this clinical experiment?
"At this juncture, enrollment for this trial is not an option. It was initially posted on September 19th 2019 and most recently updated November 23rd 2022. If you are in search of other studies, 15 rabies trials and 13 ChAd155-RG clinicals are currently accepting participants."
Is enrollment still possible in this clinical trial?
"Unfortunately, recruitment for this trial has ended. It was first posted on September 19th 2019 and the last update occurred on November 23rd 2022. If you are looking to join a clinical study, there are currently 15 rabies studies accepting participants and 13 ChAd155-RG trials open for enrollment."
Has the Food and Drug Administration accepted ChAd155-RG for medical use?
"The safety profile of ChAd155-RG is estimated to be a 1 because this pharmaceutical is currently in the initial stages of clinical trials, thus having limited evidence supporting its efficacy and security."
Can you elaborate on any prior experiments that have included ChAd155-RG?
"Presently, there are 13 ChAd155-RG studies taking place. Of these live trials, 4 have progressed to Phase 3 of the assessment process. Pathum Wan in Bangkok houses many of these investigations but 22 other locations across the world are also running similar experiments with this vaccine candidate."
Share this study with friends
Copy Link
Messenger